Severin Schwan, CEO of Swiss pharma giant Roche, has warned that the demand for Covid-19 tests still outstrips supply, making more broad-based testing challenging.
This content was published on
2 minutes
Keystone-SDA/jdp
“It is very likely that vaccines will only be broadly available later next year so I expect the demand to outstrip supply for a number of months and even beyond then,” Schwan said in a briefing to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA).
Since the start of the pandemic, Roche has been a major developer of tests to detect and diagnose Covid-19. It has received Emergency Use Authorization from the US authorities for its PCR diagnostic as well as antibodies tests, while it has also developed a test to differentiate between flu and Covid-19 strains.
Schwan said it will be important even beyond the pandemic to use testing to distinguish between diseases showing similar symptoms, such as influenza.
Targeted vs mass testing
While some neighbouring countries such as Austria have pushed for more widespread testing, Switzerland has up to now encouraged testing only for people showing Covid-19 symptoms. A few days ago, Graubünden became the first canton to launch a pilot programme to conduct mass testing of residents as part of its measures to shore up the ski season.
Schwan acknowledged that testing more broadly offers an opportunity to open up the economy but said the quantities are simply not available. “It is important that testing is prioritised. First, we need to take care of symptomatic patients and healthcare workers. Only if volumes allow for broader testing, should we go in this direction,” he said during the briefing.
SWISS international airlines announced at the end of September that it would start testing passengers on certain flights with tests developed by Roche.
Although PCR tests remain the gold standard in Covid-19 testing, Schwan said that rapid antigen tests can be produced at much larger scale – which could open the door for broader coverage of the population.
What factors should be taken into account when inheriting Swiss citizenship abroad?
Should there be a limit to the passing on of Swiss citizenship? Or is the current practice too strict and it should still be possible to register after the age of 25?
Is your place of origin, your Heimatort, important to you?
Every Swiss citizen has a Heimatort, a place of origin, but many have never visited theirs. What’s your relationship with your Heimatort? What does it mean to you?
Trump tariffs: ‘I’m a bit perplexed’, says former US ambassador to Switzerland
This content was published on
The former US ambassador to Switzerland, Edward McMullen, says he is optimistic for the Alpine country with regard to the 31% tariff on imports imposed by US President Donald Trump.
Swiss Federal Court upholds Beny Steinmetz’s bribery conviction
This content was published on
Switzerland's highest court has upheld the conviction of French-Israeli mining magnate Beny Steinmetz for bribery of foreign public officials.
This content was published on
The Trump administration has imposed a 31% tariff on imports from Switzerland. Swiss President Karin Keller-Sutter has warned against "giving in to alarmism" in an interview published on Saturday,
This content was published on
Scientists have shown that bonobos combine their calls into complex sound sequences that resemble combinations of human words.
This content was published on
US parliamentarians have threatened the UN Human Rights Council with sanctions similar to those against the International Criminal Court (ICC).
This content was published on
Thanks to abundant snowfall, lift operators benefited from increased visitor numbers, with the number of guests jumping by 12% year-on-year.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Roche poised to launch mass Covid testing
This content was published on
Swiss drug firm Roche says it is to launch a new Covid-19 antigen test before the end of the year, allowing faster, higher-volume testing.
This content was published on
Swiss firm Roche receives US Emergency Use Authorization for a test to quickly detect whether a patient has Covid-19 or one of two forms of flu.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.